[Individualized "minimal invasive" anticoagulation controlled with D-dimer-antigen testing - a concept].
The aim of the proposed concept is to use anticoagulant therapy in prophylaxis and therapy of thromboembolic events only to an extent that the coagulation activation is just not any longer detectable. It results an individualized anticoagulation tailored to the coagulation activation of the patient (individualized "minimal invasive" anticoagulation). Intensity and control of efficiency are to be monitored by measurement of in vivo coagulation activation, e.g. by D-dimer-antigen measurement. Especially with the use of the new oral anticoagulants such a saver anticoagulant therapy - as far as possible from bleeding risk - could open up new indications, which so far are not used because of safety reasons. More patients at risk could be prevented from thromboembolic events. The proposed concept is based on pathophysiological considerations and own clinical experience. It should be evaluated for efficiency in clinical studies.
Medizinisches Versorgungszentrum, Labor Ludwigsburg.
W
W
Müller-Beissenhirtz
H
H
Boschert
H
H
Müller-Beissenhirtz
D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D000933:Antifibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005338:Fibrin Fibrinogen Degradation Products / Q000008:administration & dosage / Q000627:therapeutic use*; D040261:Harm Reduction; D006801:Humans; D012306:Risk; D013923:Thromboembolism / Q000188:drug therapy* / Q000503:physiopathology; D013927:Thrombosis / Q000188:drug therapy
D000925:Anticoagulants; D000933:Antifibrinolytic Agents; D005338:Fibrin Fibrinogen Degradation Products; C036309:fibrin fragment D